Table 5 Predicted time for normalisation of leucine (efficacy set)
Children (N = 18) | Adults (N = 67) | All (N = 85) | ||
|---|---|---|---|---|
Leucine at admission | ||||
Value (μmol/L) | Mean (SD) | 863 (266) | 964 (242) | 943 (249) |
Median [min; max] | 869 [396; 1243] | 968 [518; 1685] | 961 [396; 1685] | |
Category | 381–762 (µmol/L) | 7 (38.9%) | 11 (16.4%) | 18 (21.2%) |
> 762 µmol/L | 11 (61.1%) | 56 (83.6%) | 67 (78.8%) | |
Predicted time of leucine normalisation (in days) | ||||
Based on average leucine tolerance | Mean (SD) | 3.6 (1.6) | 5.5 (1.9) | 5.1 (2.0) |
Median [min; max] | 3.6 [1.3; 6.3] | 5.0 [3.2; 12.4] | 4.8 [1.3; 12.4] | |
Observed time of leucine normalisation (in days) | ||||
For [Leu] < 381 μmol/L during episode | Mean (SD) | 2.7 (1.1) | 3.0 (1.3) | 3.0 (1.2) |
Median [min; max] | 2.0 [1.0; 6.0] | 3.0 [1.0; 7.0] | 3.0 [1.0; 7.0] | |
Reduction in time compared with predicted time to leucine normalisation (%) | 41% | 25% | 45% | |